3 Reasons Not to Worry About Sarepta Therapeutics Inc.
Sarepta Therapeutics fell on its 144-week data, but the approvability -- based on trials run by PTC Therapeutics and Prosensa -- is likely to be based on 48-week data.
Down 17%: Is Sarepta a Bad News Buy?
Sarepta Therapeutics is down over 20% today on disappointing clinical trial news. Here's what you need to know.
Why Wall Street is Betting Heavily Against Sarepta Therapeutics
Despite the FDA recently providing a regulatory pathway for Sarepta's Duchenne muscular dystrophy drug, the stock is still one of the most heavily shorted in health care. Here's why.
Why PTC Therapeutics Inc. Shares Took Off
PTC shares soar after receiving positive comments from Credit Suisse. However, here's what shareholders should really be focused on.
What You Need to Know About PTC Therapeutics' Promising DMD Drug
PTC Therapeutics (PTCT) won support from a key EU advisory committee last month, potentially clearing the way for a drug launch next year.
Surprising MS Drug Approval: Time to Buy?
The EU has issued a preliminary approval for Translarn, the Duchenne muscular dystrophy drug developed by PTC Therapeutics.
Why Ballard Power Systems, PTC Therapeutics, and VIVUS Are Today's 3 Best Stocks
The S&P 500 hits an intraday record high before falling, while Ballard Power Systems, PTC Therapeutics, and VIVUS put smiles on their shareholders' faces.
Is Prosensa Holding About to Soar?
Clinical-stage biotechs developing treatments for Duchenne muscular dystrophy have recently won a handful of political battles that have helped their drugs move forward on the regulatory front. Could Prosena be the next company to benefit from this change in political sentiment?